Structure Therapeutics (NASDAQ:GPCR) Trading 12.2% Higher – Should You Buy?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) was up 12.2% during mid-day trading on Tuesday . The company traded as high as $74.10 and last traded at $77.8370. Approximately 314,377 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 900,331 shares. The stock had previously closed at $69.36.

Analyst Upgrades and Downgrades

GPCR has been the topic of several research analyst reports. Morgan Stanley lifted their price target on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Piper Sandler reiterated an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Stifel Nicolaus lifted their price objective on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Finally, Citizens Jmp upped their price objective on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.11.

Structure Therapeutics Stock Up 13.9%

The stock has a market capitalization of $4.79 billion, a PE ratio of -64.72 and a beta of -2.05. The firm’s fifty day moving average is $51.24 and its 200-day moving average is $32.46.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Ameriprise Financial Inc. increased its holdings in shares of Structure Therapeutics by 7.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after purchasing an additional 106,389 shares in the last quarter. Casdin Capital LLC increased its holdings in Structure Therapeutics by 26.9% in the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after buying an additional 330,000 shares in the last quarter. Millennium Management LLC lifted its position in shares of Structure Therapeutics by 4.5% during the 3rd quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock valued at $35,687,000 after acquiring an additional 54,496 shares during the period. Orbimed Advisors LLC boosted its stake in shares of Structure Therapeutics by 49.5% during the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after acquiring an additional 397,272 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Structure Therapeutics by 0.5% in the 3rd quarter. Franklin Resources Inc. now owns 745,734 shares of the company’s stock worth $20,881,000 after acquiring an additional 3,951 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.